MRKR official logo MRKR
MRKR 1-star rating from Upturn Advisory
Marker Therapeutics Inc (MRKR) company logo

Marker Therapeutics Inc (MRKR)

Marker Therapeutics Inc (MRKR) 1-star rating from Upturn Advisory
$1.28
Last Close (24-hour delay)
Profit since last BUY4.92%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 15 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/17/2025: MRKR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

1 star rating from financial analysts

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $7.33

1 Year Target Price $7.33

Analysts Price Target For last 52 week
$7.33 Target price
52w Low $0.81
Current$1.28
52w High $3.95

Analysis of Past Performance

Type Stock
Historic Profit -12.24%
Avg. Invested days 27
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/17/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 16.43M USD
Price to earnings Ratio -
1Y Target Price 7.33
Price to earnings Ratio -
1Y Target Price 7.33
Volume (30-day avg) 2
Beta 1.35
52 Weeks Range 0.81 - 3.95
Updated Date 12/16/2025
52 Weeks Range 0.81 - 3.95
Updated Date 12/16/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.17

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -173.3%

Management Effectiveness

Return on Assets (TTM) -55.2%
Return on Equity (TTM) -110.67%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 3834990
Price to Sales(TTM) 3.5
Enterprise Value 3834990
Price to Sales(TTM) 3.5
Enterprise Value to Revenue 0.87
Enterprise Value to EBITDA -0.22
Shares Outstanding 12938910
Shares Floating 13676466
Shares Outstanding 12938910
Shares Floating 13676466
Percent Insiders 5.49
Percent Institutions 20.7

About Marker Therapeutics Inc

Exchange NASDAQ
Headquaters Houston, TX, United States
IPO Launch date 2014-03-25
Co-Founder, CEO, President, Treasurer, Secretary & Director Dr. Juan F. Vera M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 5
Full time employees 5

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.